UniQure stock surges 247% after mid-stage Huntington’s win
The Dutch biotech will now file for AMT-130’s approval in Huntington’s disease.
25 September 2025
25 September 2025
The Dutch biotech will now file for AMT-130’s approval in Huntington’s disease.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.